Biohaven Ltd. BHVN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
18/100
Weak

About Biohaven Ltd.

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment … Full BHVN analysis →

Competitive advantage assessment

Key risks

  • ROIC Below WACC or Peers ROIC at 14.1th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.21), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where BHVN ranks in Biotechnology

Biohaven Ltd. ranks #618 of 713 scored companies in Biotechnology by moat score — the top 87%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near BHVN in Biotechnology
# Company Moat score Rating
614 Nuvectis Pharma, Inc. NVCT 18/100 Weak
615 Virax Biolabs Group Limited VRAX 18/100 Weak
616 Azitra Inc AZTR 18/100 Weak
617 BioVie Inc. BIVI 18/100 Weak
618 Biohaven Ltd. BHVN 18/100 Weak
619 Inhibrx Biosciences, Inc. INBX 17/100 Weak
620 CervoMed Inc. CRVO 17/100 Weak
621 Jupiter Neurosciences, Inc. JUNS 17/100 Weak
622 Soligenix, Inc. SNGX 17/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How BHVN scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 12 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 27 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BHVN's moat

What is Biohaven Ltd.'s moat score?

Biohaven Ltd. (BHVN) scores 18 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #618 of 713 scored companies in Biotechnology, the top 87%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (27/100) and its weakest is Capital Efficiency (12/100).

How does Biohaven Ltd. compare with other Biotechnology companies?

Biohaven Ltd. ranks #618 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are BioVie Inc. (BIVI) at 18 just above it and Inhibrx Biosciences, Inc. (INBX) at 17 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Biohaven Ltd. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Biohaven Ltd.?

The Corporate Default template measures 6 defenses, and BHVN scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (12), Resilience (27), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000